APO Research
Talk to an analyst

APO RESEARCH · REPORT

Xeljanz (tofacitnib) Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Xeljanz (tofacitnib) Drug Industry Growth and Trends Forecast to 2032

22 December 202571 pages

Choose your research edition.

Industry ResearchXeljanz (tofacitnib) Drug Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Xeljanz (tofacitnib) Drug Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Xeljanz (tofacitnib) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Xeljanz (tofacitnib) Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Xeljanz (tofacitnib) Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Xeljanz (tofacitnib) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Xeljanz (tofacitnib) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Xeljanz (tofacitnib) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Xeljanz (tofacitnib) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Xeljanz (tofacitnib) Drug include Pfizer. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Xeljanz (tofacitnib) Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Xeljanz (tofacitnib) Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Xeljanz (tofacitnib) Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Xeljanz (tofacitnib) Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Xeljanz (tofacitnib) Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Xeljanz (tofacitnib) Drug Market by Company

Pfizer

Xeljanz (tofacitnib) Drug Segment by Type

Tablets

Extended-release Tablets

Xeljanz (tofacitnib) Drug Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Other

Xeljanz (tofacitnib) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Xeljanz (tofacitnib) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Xeljanz (tofacitnib) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Xeljanz (tofacitnib) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Xeljanz (tofacitnib) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Xeljanz (tofacitnib) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Tablets Table 2. Major Company of Extended-release Tablets Table 3. Global Xeljanz (tofacitnib) Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 5. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Xeljanz (tofacitnib) Drug Price by Type (2021-2026) & (US$/unit) Table 9. Global Xeljanz (tofacitnib) Drug Sales by Type (2027-2032) & (k units) Table 10. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Xeljanz (tofacitnib) Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Xeljanz (tofacitnib) Drug Price by Type (2027-2032) & (US$/unit) Table 14. North America Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 15. North America Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 17. Europe Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 21. Latin America Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Xeljanz (tofacitnib) Drug Industry Trends Table 25. Xeljanz (tofacitnib) Drug Industry Drivers Table 26. Xeljanz (tofacitnib) Drug Industry Opportunities and Challenges Table 27. Xeljanz (tofacitnib) Drug Industry Restraints Table 28. Global Xeljanz (tofacitnib) Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Company (2021-2026) Table 30. Global Xeljanz (tofacitnib) Drug Sales by Company (2021-2026) & (k units) Table 31. Global Xeljanz (tofacitnib) Drug Sales Share by Company (2021-2026) Table 32. Global Xeljanz (tofacitnib) Drug Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Xeljanz (tofacitnib) Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Xeljanz (tofacitnib) Drug Major Company Production Sites and Headquarters Table 35. Global Xeljanz (tofacitnib) Drug Company, Product Type & Application Table 36. Global Xeljanz (tofacitnib) Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Xeljanz (tofacitnib) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Xeljanz (tofacitnib) Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Xeljanz (tofacitnib) Drug Sales by Region (2021-2026) & (k units) Table 41. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Xeljanz (tofacitnib) Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Xeljanz (tofacitnib) Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Xeljanz (tofacitnib) Drug Sales by Region (2027-2032) & (k units) Table 46. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Xeljanz (tofacitnib) Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Xeljanz (tofacitnib) Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Xeljanz (tofacitnib) Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 52. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Xeljanz (tofacitnib) Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Xeljanz (tofacitnib) Drug Sales by Application (2027-2032) & (k units) Table 57. Global Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Xeljanz (tofacitnib) Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Xeljanz (tofacitnib) Drug Price by Application (2027-2032) & (US$/unit) Table 61. North America Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 62. North America Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 64. Europe Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 68. Latin America Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Xeljanz (tofacitnib) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Pfizer Xeljanz (tofacitnib) Drug Product Portfolio Table 75. Pfizer Recent Development Table 76. North America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 77. North America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units) Table 78. North America Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2026) Table 79. North America Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032) & (k units) Table 80. North America Xeljanz (tofacitnib) Drug Sales Market Share Forecast by Country (2027-2032) Table 81. North America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 82. North America Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026) & (US$ Million) Table 83. North America Xeljanz (tofacitnib) Drug Market Share by Country (2021-2026) Table 84. North America Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 85. North America Xeljanz (tofacitnib) Drug Market Share Forecast by Country (2027-2032) Table 86. Europe Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 87. Europe Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units) Table 88. Europe Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2026) Table 89. Europe Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032) & (k units) Table 90. Europe Xeljanz (tofacitnib) Drug Sales Market Share Forecast by Country (2027-2032) Table 91. Europe Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 92. Europe Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026) & (US$ Million) Table 93. Europe Xeljanz (tofacitnib) Drug Market Share by Country (2021-2026) Table 94. Europe Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 95. Europe Xeljanz (tofacitnib) Drug Market Share Forecast by Country (2027-2032) Table 96. Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 97. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units) Table 98. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2026) Table 99. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032) & (k units) Table 100. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026) & (US$ Million) Table 103. Asia-Pacific Xeljanz (tofacitnib) Drug Market Share by Country (2021-2026) Table 104. Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. Asia-Pacific Xeljanz (tofacitnib) Drug Market Share Forecast by Country (2027-2032) Table 106. Latin America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 107. Latin America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units) Table 108. Latin America Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2026) Table 109. Latin America Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032) & (k units) Table 110. Latin America Xeljanz (tofacitnib) Drug Sales Market Share Forecast by Country (2027-2032) Table 111. Latin America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Latin America Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026) & (US$ Million) Table 113. Latin America Xeljanz (tofacitnib) Drug Market Share by Country (2021-2026) Table 114. Latin America Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Latin America Xeljanz (tofacitnib) Drug Market Share Forecast by Country (2027-2032) Table 116. Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 117. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units) Table 118. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2026) Table 119. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032) & (k units) Table 120. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026) & (US$ Million) Table 123. Middle East and Africa Xeljanz (tofacitnib) Drug Market Share by Country (2021-2026) Table 124. Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Middle East and Africa Xeljanz (tofacitnib) Drug Market Share Forecast by Country (2027-2032) Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Xeljanz (tofacitnib) Drug Distributors List Table 129. Xeljanz (tofacitnib) Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Xeljanz (tofacitnib) Drug Image Figure 2. Global Xeljanz (tofacitnib) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Xeljanz (tofacitnib) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Xeljanz (tofacitnib) Drug Sales (2021-2032) & (k units) Figure 5. Tablets Image Figure 6. Global Tablets Sales YoY Growth (2021-2032) & (k units) Figure 7. Extended-release Tablets Image Figure 8. Global Extended-release Tablets Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Xeljanz (tofacitnib) Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Xeljanz (tofacitnib) Drug Market Share by Type 2025 VS 2032 Figure 11. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Xeljanz (tofacitnib) Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Rheumatoid Arthritis Image Figure 24. Global Rheumatoid Arthritis Sales YoY Growth (2021-2032) & (k units) Figure 25. Psoriatic Arthritis Image Figure 26. Global Psoriatic Arthritis Sales YoY Growth (2021-2032) & (k units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Xeljanz (tofacitnib) Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Xeljanz (tofacitnib) Drug Market Share by Application 2025 VS 2032 Figure 31. North America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Market Share in Value by Application in 2025 Figure 41. North America Xeljanz (tofacitnib) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Xeljanz (tofacitnib) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Xeljanz (tofacitnib) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Xeljanz (tofacitnib) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Xeljanz (tofacitnib) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Xeljanz (tofacitnib) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Xeljanz (tofacitnib) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Xeljanz (tofacitnib) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Xeljanz (tofacitnib) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Xeljanz (tofacitnib) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Xeljanz (tofacitnib) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Xeljanz (tofacitnib) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Xeljanz (tofacitnib) Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Xeljanz (tofacitnib) Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Extended-release Tablets
Applications
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Xeljanz (tofacitnib) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Xeljanz (tofacitnib) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Xeljanz (tofacitnib) Drug Market by Type
  6. 1.3.1 Tablets
  7. 1.3.2 Extended-release Tablets
  8. 1.4 Global Xeljanz (tofacitnib) Drug Market Size by Type
  9. 1.4.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Xeljanz (tofacitnib) Drug Industry Trends
  2. 2.2 Xeljanz (tofacitnib) Drug Industry Drivers
  3. 2.3 Xeljanz (tofacitnib) Drug Industry Opportunities and Challenges
  4. 2.4 Xeljanz (tofacitnib) Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Xeljanz (tofacitnib) Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Xeljanz (tofacitnib) Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Xeljanz (tofacitnib) Drug Price (2021-2026)
  4. 3.4 Global Xeljanz (tofacitnib) Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Xeljanz (tofacitnib) Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Xeljanz (tofacitnib) Drug Company, Product Type & Application
  7. 3.7 Global Xeljanz (tofacitnib) Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Xeljanz (tofacitnib) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Xeljanz (tofacitnib) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Xeljanz (tofacitnib) Drug Tier 1, Tier 2, and Tier 3
4 Xeljanz (tofacitnib) Drug Regional Status and Outlook
  1. 4.1 Global Xeljanz (tofacitnib) Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Xeljanz (tofacitnib) Drug Historic Market Size by Region
  3. 4.2.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Region
  7. 4.3.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Xeljanz (tofacitnib) Drug by Application
  1. 5.1 Xeljanz (tofacitnib) Drug Market by Application
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 Psoriatic Arthritis
  4. 5.1.3 Other
  5. 5.2 Global Xeljanz (tofacitnib) Drug Market Size by Application
  6. 5.2.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Xeljanz (tofacitnib) Drug Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
7 North America by Country
  1. 7.1 North America Xeljanz (tofacitnib) Drug Sales by Country
  2. 7.1.1 North America Xeljanz (tofacitnib) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Xeljanz (tofacitnib) Drug Market Size by Country
  6. 7.2.1 North America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Xeljanz (tofacitnib) Drug Sales by Country
  2. 8.1.1 Europe Xeljanz (tofacitnib) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Xeljanz (tofacitnib) Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Xeljanz (tofacitnib) Drug Market Size by Country
  6. 8.2.1 Europe Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Country
  2. 9.1.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Xeljanz (tofacitnib) Drug Sales by Country
  2. 10.1.1 South America Xeljanz (tofacitnib) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Xeljanz (tofacitnib) Drug Market Size by Country
  6. 10.2.1 South America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country
  2. 11.1.1 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Xeljanz (tofacitnib) Drug Value Chain Analysis
  2. 12.1.1 Xeljanz (tofacitnib) Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Xeljanz (tofacitnib) Drug Production Mode & Process
  7. 12.2 Xeljanz (tofacitnib) Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Xeljanz (tofacitnib) Drug Distributors
  10. 12.2.3 Xeljanz (tofacitnib) Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst